Information  X 
Enter a valid email address

Diurnal Group PLC (DNL)

  Print      Mail a friend

Friday 18 May, 2018

Diurnal Group PLC

Appointment of NOMAD and Joint Broker

RNS Number : 5487O
Diurnal Group PLC
18 May 2018
 

18 May 2018

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Appointment of NOMAD and Joint Broker

 

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the appointment of Panmure Gordon (UK) Limited (Panmure) as Nominated Adviser to the Company and Cantor Fitzgerald Europe as joint broker to the Company, with immediate effect. Panmure remains joint broker to the Company. 

 

 

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer


Richard Bungay, Chief Financial Officer




Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley, Emma Earl


Corporate Broking: James Stearns




Cantor Fitzgerald Europe (Joint Broker)

+44 (0) 20 7894 7000

Corporate Finance: Phil Davies, Will Goode, Michael Boot


Healthcare Equity Sales: Andrew Keith




FTI Consulting (Media and Investor Relations)

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


 

 

Notes to Editors

 

About Diurnal

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
APPLIFITERITLIT

a d v e r t i s e m e n t